About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
ESMO 2024 Insights: Nivo + Ipi ± ASTX727 in Anti-PD-1 Resistant Metastatic Melanoma - NIBIT-ML1 Ph2 Study
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Anna Maria Di Giacomo
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Anna Maria Di Giacomo
42 views
September 20, 2024
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
17:50
AdventHealth
Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…
Feat.
G. Sonpavde
24:14
Masterclasses in Dermatology
Advances in the Treatment of Melanoma
Feat.
D. Fisher
12:46
Stanford Medicine
FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …
Feat.
A. Betof Warner
35:23
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "My Personal Highlights in Melanoma"
Feat.
S. Patel
10:01
AAD 2024
AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma
Feat.
V. Sondak
11:05
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, …
Feat.
D. Johnson
09:26
Oncology Data Advisor
The NADINA Trial - A Paradigm Shift in Melanoma Treatment
Feat.
M. Hadfield
22:58
Tarek Haykal
The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…
25:29
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Insights in Melanoma"
Feat.
O. Hamid
09:54
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Ou…
Feat.
H. Tawbi
18:28
Vanderbilt University Medical Center (VUMC)
NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…
Feat.
D. Johnson
24:27
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…
Feat.
Z. Eroglu
14:42
Jeff Yorio
Optimal Treatment for BRAF-Mutated Metastatic Melanoma
08:41
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in …
Feat.
C. Blank
22:27
2024 ASCO® Annual Meeting Insights Hub
Developmental Therapeutics Highlights From ASCO® 2024
Feat.
G. Sonpavde
11:27
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We B…
Feat.
P. Corrie
17:07
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Melanoma Brain Metastases: Successes, Failures, and Future Opportuni…
Feat.
M. Postow
28:32
West Virginia State Rheumatology Society
Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers
Feat.
J. Bustamante
07:23
Mees Egeler
Long-Term Side Effects Associated With IO Treatment vs. TT in Adjuva…
23:09
Total Health
Key Updates in Skin Melanoma
Feat.
R. Seedor
